Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma

Trial ID #	NCT00072566
Phase	II
Drug Class	Angiogenesis Inhibitors: VEGF
Drug Name	Bevacizumab
Alternate Drug Names	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial	Cyclophosphamide, Bevacizumab
Eligible Participant	Recurrent ovarian cancer with ≤3 prior therapies
Patients Enrolled	70, median 2 prior therapies
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, DoR, PFS, evaluated per RECIST
Efficacy	ORR: 24% (17PR, n=70) DCR: 87% (17PR, 44SD, n=70) PFS: 7.2 months OS: 16.9 months
Clinically Significant Adverse Events	Serious AE: three deaths, two pulmonary hypertension, one gastrointestinal perforation Grade 3-4 AE: lymphopenia (20%), pain (19%), hypertension (16%)
Conclusion	Promising response rates of bevacizumab+cyclophosphamide combination
Reference	Garcia AA et al. Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol (2008) 26(1): 76-82 https://www.ncbi.nlm.nih.gov/pubmed/18165643